Evaluation of a multicomponent intervention to shorten thrombolytic door-to-needle time in stroke patients in China (MISSION): A cluster-randomized controlled trial

Wansi Zhong, Longting Lin, Xiaoxian Gong, Zhicai Chen, Yi Chen, Shenqiang Yan, Ying Zhou, Xuting Zhang, Haitao Hu, Lusha Tong, Chaochan Cheng, Qun Gu, Yong Chen, Xiaojin Yu, Yuhui Huang, Changzheng Yuan, Min Lou, MISSION investigators, Wansi Zhong, Longting Lin, Xiaoxian Gong, Zhicai Chen, Yi Chen, Shenqiang Yan, Ying Zhou, Xuting Zhang, Haitao Hu, Lusha Tong, Chaochan Cheng, Qun Gu, Yong Chen, Xiaojin Yu, Yuhui Huang, Changzheng Yuan, Min Lou, MISSION investigators

Abstract

Background: Rapid intravenous thrombolysis (IVT) for acute ischemic stroke (AIS) is crucial for improving outcomes. However, few randomized trials of interventions aimed at reducing in-hospital delay have been carried out in China. We aimed to evaluate the effect of a multicomponent intervention on thrombolytic door-to-needle time (DNT) of AIS patients via video teleconference based on the Behavior Change Wheel (BCW) method.

Methods and findings: This cluster-randomized trial, conducted between January 1, 2019 and December 31, 2019, randomly allocated 22 hospitals equally to PEITEM (Persuasion Environment reconstruction Incentivization Training Education Modeling) intervention or routine care plus stroke registry and subsequently enrolled 1,634 AIS patients receiving IVT within 4.5 hours upon stroke onset from participant hospitals. The PEITEM group received a 1-year PEITEM 6-component intervention based on the behavioral theory monthly via video teleconference. The primary outcome was the proportion of patients with a DNT of 60 minutes or less. A total of 987 patients participated in the PEITEM group (mean age, 69 years; female, 411 [41.6%]) and 647 patients in the control group (mean age, 70 years; female, 238 [36.8%]). Of all participants, the proportion of DNT ≤60 minutes in the PEITEM group was higher than in the control group (82.0% versus 73.3%; adjusted odds ratio, 1.77; 95% confidence interval (CI), 1.17 to 2.70; ICC, 0.04; P = 0.007). Among secondary outcomes, the average DNT was 43 minutes in the PEITEM group and 50 minutes in the control group (adjusted mean difference: -8.83; 95% CI, -14.03 to -3.64; ICC, 0.12; P = 0.001). Favorable functional outcome (score of 0 to 1 on the modified Rankin scale (mRS)) was achieved in 55.6% patients of the PEITEM group and 50.4% of the control group (adjusted odds ratio, 1.38; 95% CI, 1.00 to 1.90; ICC, 0.01; P = 0.049). Main study limitations include non-blinding of clinicians, and that specific interventions component responsible for the observed changes could not be determined.

Conclusions: The teleconference-delivered PEITEM intervention resulted in a moderate but clinically relevant shorter DNT and better functional outcome in AIS patients receiving IVT.

Trial registration: Clinicaltrials.gov NCT03317639.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Flow of hospitals and patients…
Fig 1. Flow of hospitals and patients through the study.
mRS, modified Rankin scale; PEITEM, Persuasion Environment reconstruction Incentivization Training Education Modeling; sICH, symptomatic intracranial hemorrhage.
Fig 2. The proportion of AIS patients…
Fig 2. The proportion of AIS patients for different door-to-needle times in the PEITEM group and control group.
AIS, acute ischemic stroke; DNT, door-to-needle time; PEITEM, Persuasion Environment reconstruction Incentivization Training Education Modeling.
Fig 3. Distribution of modified Rankin scores…
Fig 3. Distribution of modified Rankin scores at 90 days among eligible patients with AIS receiving PEITEM intervention vs. routine care and stroke registry participation group (control).
AIS, acute ischemic stroke; PEITEM, Persuasion Environment reconstruction Incentivization Training Education Modeling.

References

    1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al.. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110. Epub 2018/01/26. doi: 10.1161/STR.0000000000000158 .
    1. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al.. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379(9834):2364–72. Epub 2012/05/29. doi: 10.1016/S0140-6736(12)60738-7 ; PubMed Central PMCID: PMC3386494.
    1. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al.. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–703. Epub 2010/05/18. doi: 10.1016/S0140-6736(10)60491-6 .
    1. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, et al.. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55(11):1649–55. Epub 2000/12/13. doi: 10.1212/wnl.55.11.1649 .
    1. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al.. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929–35. Epub 2014/08/12. doi: 10.1016/S0140-6736(14)60584-5 ; PubMed Central PMCID: PMC4441266.
    1. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40(6):2079–84. Epub 2009/04/18. doi: 10.1161/STROKEAHA.108.540708 ; PubMed Central PMCID: PMC2881642.
    1. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al.. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480–8. Epub 2013/06/20. doi: 10.1001/jama.2013.6959 .
    1. Xian Y, Xu H, Lytle B, Blevins J, Peterson ED, Hernandez AF, et al.. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. Circ Cardiovasc Qual Outcomes. 2017;10(1). Epub 2017/01/18. doi: 10.1161/CIRCOUTCOMES.116.003227 .
    1. Wang YJ, Li ZX, Gu HQ, Zhai Y, Jiang Y, Zhao XQ, et al.. China Stroke Statistics 2019: A Report From the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. Stroke Vasc Neurol. 2020;5(3):211–39. Epub 2020/08/23. doi: 10.1136/svn-2020-000457 ; PubMed Central PMCID: PMC7548521.
    1. Wang Y, Liao X, Zhao X, Wang DZ, Wang C, Nguyen-Huynh MN, et al.. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke. 2011;42(6):1658–64. Epub 2011/04/23. doi: 10.1161/STROKEAHA.110.604249 .
    1. Yang J, Wang X, Yu JP, Hang J, Lavados P, Robinson T, et al.. Positive impact of the participation in the ENCHANTED trial in reducing Door-to-Needle Time. Sci Rep. 2017;7(1):14168. Epub 2017/10/28. doi: 10.1038/s41598-017-14164-8 ; PubMed Central PMCID: PMC5658430.
    1. Kamal N, Holodinsky JK, Stephenson C, Kashayp D, Demchuk AM, Hill MD, et al.. Improving Door-to-Needle Times for Acute Ischemic Stroke: Effect of Rapid Patient Registration, Moving Directly to Computed Tomography, and Giving Alteplase at the Computed Tomography Scanner. Circ Cardiovasc Qual Outcomes. 2017;10(1). Epub 2017/01/18. doi: 10.1161/CIRCOUTCOMES.116.003242 .
    1. Kim SK, Lee SY, Bae HJ, Lee YS, Kim SY, Kang MJ, et al.. Pre-hospital notification reduced the door-to-needle time for iv t-PA in acute ischaemic stroke. Eur J Neurol. 2009;16(12):1331–5. Epub 2009/10/17. doi: 10.1111/j.1468-1331.2009.02762.x .
    1. Tran D, Zhu Z, Shafie M, Abcede H, Stradling D, Yu W. Three easily-implementable changes reduce median door-to-needle time for intravenous thrombolysis by 23 minutes. BMC Neurol. 2019;19(1):300. Epub 2019/11/28. doi: 10.1186/s12883-019-1527-8 ; PubMed Central PMCID: PMC6878675.
    1. Xian Y, Smith EE, Zhao X, Peterson ED, Olson DM, Hernandez AF, et al.. Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. Stroke. 2014;45(5):1387–95. Epub 2014/04/10. doi: 10.1161/STROKEAHA.113.003898 .
    1. Kamal N, Jeerakathil T, Stang J, Liu M, Rogers E, Smith EE, et al.. Provincial Door-to-Needle Improvement Initiative Results in Improved Patient Outcomes Across an Entire Population. Stroke. 2020;51(8):2339–46. Epub 2020/07/10. doi: 10.1161/STROKEAHA.120.029734 .
    1. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. Epub 2011/04/26. doi: 10.1186/1748-5908-6-42 ; PubMed Central PMCID: PMC3096582.
    1. Chiang N, Guo M, Amico KR, Atkins L, Lester RT. Interactive Two-Way mHealth Interventions for Improving Medication Adherence: An Evaluation Using The Behaviour Change Wheel Framework. JMIR Mhealth Uhealth. 2018;6(4):e87. Epub 2018/04/14. doi: 10.2196/mhealth.9187 ; PubMed Central PMCID: PMC5920150.
    1. Gould GS, Bar-Zeev Y, Bovill M, Atkins L, Gruppetta M, Clarke MJ, et al.. Designing an implementation intervention with the Behaviour Change Wheel for health provider smoking cessation care for Australian Indigenous pregnant women. Implement Sci. 2017;12(1):114. Epub 2017/09/17. doi: 10.1186/s13012-017-0645-1 ; PubMed Central PMCID: PMC5602934.
    1. Sinnott C, Mercer SW, Payne RA, Duerden M, Bradley CP, Byrne M. Improving medication management in multimorbidity: development of the MultimorbiditY COllaborative Medication Review And DEcision Making (MY COMRADE) intervention using the Behaviour Change Wheel. Implement Sci. 2015;10:132. Epub 2015/09/26. doi: 10.1186/s13012-015-0322-1 ; PubMed Central PMCID: PMC4582886.
    1. Loft MI, Martinsen B, Esbensen BA, Mathiesen LL, Iversen HK, Poulsen I. Strengthening the role and functions of nursing staff in inpatient stroke rehabilitation: developing a complex intervention using the Behaviour Change Wheel. Int J Qual Stud Health Well-being. 2017;12(sup2):1392218. Epub 2017/11/02. doi: 10.1080/17482631.2017.1392218 ; PubMed Central PMCID: PMC7011965.
    1. Campbell MK, Piaggio G, Elbourne DR, Altman DG, Group C. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. Epub 2012/09/07. doi: 10.1136/bmj.e5661 .
    1. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al.. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245–51. Epub 1998/10/27. doi: 10.1016/s0140-6736(98)08020-9 .
    1. Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, et al.. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. 2014;311(16):1632–40. Epub 2014/04/24. doi: 10.1001/jama.2014.3203 .
    1. Chakraborty H, Hossain A. R package to estimate intracluster correlation coefficient with confidence interval for binary data. Comput Methods Programs Biomed. 2018;155:85–92. Epub 2018/03/08. doi: 10.1016/j.cmpb.2017.10.023 .
    1. Leyrat C, Morgan KE, Leurent B, Kahan BC. Cluster randomized trials with a small number of clusters: which analyses should be used? Int J Epidemiol. 2018;47(1):321–31. Epub 2017/10/13. doi: 10.1093/ije/dyx169 .
    1. Ajmi SC, Advani R, Fjetland L, Kurz KD, Lindner T, Qvindesland SA, et al.. Reducing door-to-needle times in stroke thrombolysis to 13 min through protocol revision and simulation training: a quality improvement project in a Norwegian stroke centre. BMJ Qual Saf. 2019;28(11):939–48. Epub 2019/07/01. doi: 10.1136/bmjqs-2018-009117 .
    1. Meretoja A, Kaste M. Pre- and in-hospital intersection of stroke care. Ann N Y Acad Sci. 2012;1268:145–51. Epub 2012/09/22. doi: 10.1111/j.1749-6632.2012.06664.x .
    1. Ashcraft S, Wilson SE, Nystrom KV, Dusenbury W, Wira CR, Burrus TM, et al.. Care of the Patient With Acute Ischemic Stroke (Prehospital and Acute Phase of Care): Update to the 2009 Comprehensive Nursing Care Scientific Statement: A Scientific Statement From the American Heart Association. Stroke. 2021;52(5):e164–e78. Epub 2021/03/12. doi: 10.1161/STR.0000000000000356 .
    1. Hasnain MG, Paul CL, Attia JR, Ryan A, Kerr E, D’Este C, et al.. Door-to-needle time for thrombolysis: a secondary analysis of the TIPS cluster randomised controlled trial. BMJ Open. 2019;9(12):e032482. Epub 2019/12/18. doi: 10.1136/bmjopen-2019-032482 ; PubMed Central PMCID: PMC6924711.
    1. Kamal N, Sheng S, Xian Y, Matsouaka R, Hill MD, Bhatt DL, et al.. Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. Stroke. 2017;48(4):946–54. Epub 2017/02/24. doi: 10.1161/STROKEAHA.116.015712 .
    1. Man S, Xian Y, Holmes DN, Matsouaka RA, Saver JL, Smith EE, et al.. Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. JAMA. 2020;323(21):2170–84. Epub 2020/06/03. doi: 10.1001/jama.2020.5697 ; PubMed Central PMCID: PMC7267850.

Source: PubMed

3
S'abonner